NCT06206941 IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer
| NCT ID | NCT06206941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2025-01-02 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2025-01-02 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety. Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.
Eligibility Criteria
Inclusion Criteria: * adult age of 21 years or older * cancer diagnosis and planning or using immunotherapy treatment, * pain and spend less than 50% in bed or chair * fluent in english language Exclusion Criteria: * use synthetic cannabis or only use Cannabidiol (CBD) * non users but used in the past 3 months * prior immunotherapy, Patients receiving immunosuppressants or organ transplant recipients. * Patients within 6 months of Hospice care. * Pain that limits movement to more than 50% of their day in bed or chair
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06206941 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06206941 currently recruiting?
Yes, NCT06206941 is actively recruiting participants. Contact the research team at rlashare@buffalo.edu for enrollment information.
Where is the NCT06206941 trial being conducted?
This trial is being conducted at Portland, United States, Philadelphia, United States.
Who is sponsoring the NCT06206941 clinical trial?
NCT06206941 is sponsored by State University of New York at Buffalo. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.